🇺🇸 FDA
Patent

US 9688987

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

granted A61PA61P1/16A61P11/00

Quick answer

US patent 9688987 (Antisense oligonucleotides directed against connective tissue growth factor and uses thereof) held by Ionis Pharmaceuticals, Inc. expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
59
CPC classes
A61P, A61P1/16, A61P11/00, A61P13/12, A61P17/00